A. Florschütz

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 101 citations · Full text

Gastrointestinal Oncology, Medicine, Pathology +8

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter Thuss‐Patience, Ralf‐Dieter Hofheinz, Dirk Arnold et al. · Annals of Oncology · 2012 · 70 citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Medicine +8

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

Tod M. Klingler, J. Riera-Knorrenschield, A. Tannapfel et al. · Annals of Oncology · 2018 · 21 citations · Full text

Surgical Oncology, Health Sciences, Gastrointestinal Oncology +14

Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia

C. Kahl, A. Florschütz, Gerd Müller et al. · Annals of Hematology · 1997 · 17 citations

Hematological Malignancy, Myelogenous Leukemia, Medicine +11

FOLFOX/bevacizumab +/- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß et al. · Annals of Oncology · 2018 · 15 citations · Full text